SBIR-STTR Award

A Combination Endovascular Device:Thrombectomy With Localized Hypothermia
Award last edited on: 11/16/11

Sponsored Program
SBIR
Awarding Agency
NIH : NINDS
Total Award Amount
$207,200
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Thomas L Merrill

Company Information

FocalCool LLC

107 Gilbreth Parkway
Mullica Hill, NJ 08062
   (856) 256-4301
   jakers@focalcool.com
   www.focalcool.com
Location: Single
Congr. District: 02
County: Gloucester

Phase I

Contract Number: 1R43NS073291-01
Start Date: 3/1/11    Completed: 2/29/12
Phase I year
2011
Phase I Amount
$207,200
Stroke is the 3rd leading cause of death and number one cause of adult disability in the United States. The primary goal of ischemic stroke treatment is quickly restoring blood perfusion. However, studies have shown that this return of blood flow, while necessary to bettering patient outcome, can cause damage to local tissue. Hypothermia has been shown to decrease this "reperfusion injury". The overall goal of this proposed research is to use therapeutic hypothermia to augment the tissue salvage capabilities of existing mechanical clot removal devices that restore perfusion by reducing reperfusion injury. Our proposed device is a cooling guide catheter which will function identically to conventional guide catheters but with blood cooling capabilities to save ischemic tissue at risk of reperfusion injury. Specific Aims: 1.) Design a cooling guide catheter that can be used with existing mechanical clot removal devices and that can quickly reduce target tissue temperatures, 2.) characterize device thermal-fluid performance in an in vitro brain model, and 3.) demonstrate that the cooling catheter can safely and effectively decrease target tissue temperature in a small animal pilot study. To achieve these aims the following will be performed: thermal-fluid modeling, design input requirements and feasibility points, development of prototype designs, coolant pressure-flow behavior characterization, in vitro thermal-fluid performance testing for each prototype in system that mimics intracranial blood flow, and in vivo testing demonstrating that rapid localized tissue cooling is feasible and that the catheter is hemocompatibile with no significant damage to vessels or tissue. Relevance: The technological innovation of combining stroke treatment therapies - mechanical clot removal and reperfusion hypothermia - may yield synergistic benefits, resulting in reduced infarct size and improved neurological outcomes compared to outcomes using either technology separately. If fast and safe cooling is shown feasible in Phase I, Phase II would investigate efficacy using an animal stroke model.

Public Health Relevance:
Stroke is the 3rd leading cause of death and number one cause of adult disability in the United States. For stroke treatment, quickly restoring blood flow has been shown to improve outcome, although some experts have found reperfusion injury mitigates these benefits. FocalCool, LLC seeks to combine two technologies, thrombectomy and therapeutic hypothermia using a novel cooling guide catheter potentially maximizing the benefit of blood flow restoration while minimizing damaging effects of reperfusion injury.

Thesaurus Terms:
21+ Years Old;Abscission;Acute;Adult;Animal Testing;Animals;Apoplexy;Attenuated;Behavior;Blood;Blood Flow;Body Tissues;Brain;Brain Region;Catheters;Cause Of Death;Cerebral Stroke;Cerebrovascular Apoplexy;Cerebrovascular Stroke;Cerebrovascular Accident;Characteristics;Clotting;Coagulation;Coagulation Process;Development;Device Removal;Devices;Encephalon;Encephalons;Environment;Excision;Extirpation;Goals;Hour;Human, Adult;Hypothermia;In Vitro;Infarction;Injury;Intervention;Intervention Strategies;Ischemia-Reperfusion Injury;Ischemic Stroke;Liquid Substance;Measures;Mechanics;Medical;Modeling;Nervous System, Brain;Neurologic Outcome;Neurological Outcome;Outcome;Patients;Performance;Perfusion;Phase;Physiologic;Physiological;Pilot Projects;Pressure;Pressure- Physical Agent;Recommendation;Removal;Reperfusion Damage;Reperfusion Injury;Reperfusion Therapy;Reporting;Research;Reticuloendothelial System, Blood;Risk;Stroke;Surgical Removal;Symptoms;System;System, Loinc Axis 4;Technology;Teflon;Temperature;Test Result;Testing;Therapeutic;Therapeutic Uses;Thrombectomy;Thrombus;Tissues;Torque;United States;Vascular Accident, Brain;Work;Adult Human (21+);Analog;Brain Attack;Brain Tissue;Cerebral Vascular Accident;Design;Designing;Disability;Fluid;Hypothermia, Natural;Improved;In Vitro Testing;In Vivo;Infarct;Interest;Interventional Strategy;Liquid;Meetings;Model;Model Design;Natural Hypothermia;Neuroprotection;Novel;Performance Tests;Perfusion (Blood);Pilot Study;Pressure;Prototype;Reperfusion;Resection;Restoration;Stroke;Technological Innovation;Usability;Volcano

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----